Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagn…
| Periodo | 2025-07 | 2025-05 | 2024-11 | 2024-08 |
|---|---|---|---|---|
| Real | $-14.40 | $-26.35 | $-12.77 | $-14.00 |
| Estimado | $-17.10 | $-9.00 | $-16.20 | $-19.50 |
| Sorpresa | +15.8% | -192.8% | +21.2% | +28.2% |
| Métrica | TRIB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 34.8% | 57.4% | -22.6% |
| Operating Margin | -34.4% | -34.4% | 0.0% |
| Net Margin | -51.6% | -32.5% | -19.2% |
| FCF Margin | -7.5% | -12.6% | +5.1% |
| ROE | — | -39.2% | — |
| ROA | -30.8% | -30.9% | +0.2% |
| Current Ratio | 1.28 | 2.73 | -1.45 |
| Debt / Equity | -0.01 | 0.28 | -0.29 |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -30.8% | — |
| ✗Flujo de caja operativo positivo | −$4M | −$12M |
| ✓Rentabilidad sobre activos al alza | -30.8% | -40.4% |
| ✓Caja operativa/activos supera al ROA | -4.1% | ROA -30.8% |
| ✓Menos deuda a largo plazo | 0.2% | 0.4% |
| ✗Mejor liquidez (ratio corriente) | 1.28 | 2.60 |
| ✗Sin aumentar el nº de acciones | 359M | 153M |
| ✓Margen bruto al alza | 34.8% | 34.2% |
| ✗Rotación de activos al alza | 0.60 | 0.96 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -7.5% |
| ✗ROCE > 10 % | -29.7% |
| ✗Ventas > 5 %/año (3 años) | -8.8% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 8.0% |
TRINITY BIOTECH PLC cotiza a 8.03 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud